← All trials
NCT06856174
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2026
- Primary completion
- Sep 20, 2027
- Completion date
- Sep 20, 2027
- First posted
- Mar 4, 2025
- Last posted
- Jul 14, 2025
- Enrollment
- 105
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- ExeltisCollaborator
- ExeltisCollaborator
- National Institute on Aging (NIA)Collaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.